Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
Definium Therapeutics (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company focused on therapies for psychiatric and neurological disorders, announced it will host a webcast at 4:30 p.m. EDT on Thursday, August 6, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Listeners can register for the webcast via this link. A replay of the webcast will be available via the Investor Relations section of the Definium Therapeutics website, ir.definiumtx.com, and archived for at least 30 days after the webcast. Those who plan on participating are advised to join 15 minutes prior to the start time.
About Definium Therapeutics
The mission of Definium Therapeutics is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Guided by a recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today’s mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX.
For more information, visit https://definiumtx.com/ and follow Definium Therapeutics on Instagram, LinkedIn and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260730702724/en/
Investor Contact:
Gitanjali Jain
VP, Head of Investor Relations
IR@definiumtx.com
Media Contact:
media@definiumtx.com
Source: Definium Therapeutics, Inc.